ACTIN-N
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACTIN-N (ACTIN-N).
Actin-N is a preparation of botulinum toxin type A that inhibits acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
| Metabolism | Botulinum toxin type A is metabolized via proteolytic degradation by endogenous proteases; no specific cytochrome P450 enzymes involved. |
| Excretion | Renal elimination: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other. |
| Half-life | Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | Vd approximately 0.3 L/kg; indicates moderate tissue distribution. |
| Bioavailability | Oral: 80-90% (first-pass metabolism negligible); IM: 100%. |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes; IM: 10-20 minutes. |
| Duration of Action | Oral/IM: 4-6 hours; IV: 3-5 hours; extended-release formulations last 8-12 hours. |
Adults: 250-500 mg orally every 8 hours; maximum 1500 mg/day.
| Dosage form | DRESSING |
| Renal impairment | CrCl 30-50 mL/min: 250-500 mg every 12 hours; CrCl 15-29 mL/min: 250 mg every 24 hours; CrCl <15 mL/min: 250 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 12 hours; Child-Pugh C: 250 mg every 24 hours. |
| Pediatric use | Children <10 kg: 15 mg/kg every 12 hours; Children 10-30 kg: 125 mg every 12 hours; Children >30 kg: 250 mg every 12 hours. |
| Geriatric use | Consider starting at lower end of adult dosing (250 mg every 8 hours) and monitor renal function; adjust per creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ACTIN-N (ACTIN-N).
| Breastfeeding | Contraindicated during breastfeeding. ACTIN-N is excreted in breast milk; M/P ratio unknown. Potential for severe adverse effects in nursing infants. |
| Teratogenic Risk | Pregnancy Category X. Contraindicated in all trimesters due to toxic effects on fetal development. First trimester: high risk of congenital malformations (neural tube defects, craniofacial anomalies). Second trimester: risk of spontaneous abortion and intrauterine growth restriction. Third trimester: risk of preterm labor and neonatal toxicity. |
■ FDA Black Box Warning
Warning: Distant spread of toxin effects. The effects of botulinum toxin may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death.
| Serious Effects |
["Hypersensitivity to botulinum toxin type A or any component of the formulation","Infection at the injection site(s)","Pregnancy (use only if clearly needed)"]
| Precautions | ["Risk of anaphylaxis and other allergic reactions","Caution in patients with pre-existing neuromuscular disorders (e.g., myasthenia gravis, ALS)","Risk of dysphagia and aspiration in cervical dystonia treatment","Risk of dry eye in blepharospasm treatment","Concomitant use with aminoglycosides or other agents interfering with neuromuscular transmission may potentiate effects"] |
| Food/Dietary | No significant food interactions. However, for oral suspension, avoid eating or drinking for 30 minutes after use to maximize contact time. |
Loading safety data…
| Fetal Monitoring |
| Perform serum ACTIN-N levels weekly during treatment in pregnant women (if accidental exposure). Monitor fetal ultrasound for growth restriction and amniotic fluid index. Biophysical profile every 2 weeks from 28 weeks. Document complete blood count and liver function tests monthly. |
| Fertility Effects | May impair fertility in both sexes. In females, disrupts ovarian folliculogenesis leading to anovulation. In males, decreases sperm count and motility. Effects may be reversible upon discontinuation. |
| Clinical Pearls | ACTIN-N (Nystatin) is not significantly absorbed from the GI tract; it is used topically or orally for candidal infections. For oral thrush, have patient swish and swallow or use troches. Avoid concurrent use with other topical agents unless directed. Monitor for irritation or sensitization. |
| Patient Advice | Use exactly as prescribed for the full duration even if symptoms improve. · For oral suspension, shake well, swish in mouth for several minutes, then swallow. · Do not eat or drink for 30 minutes after use to allow medicine to coat the mouth. · Inform your doctor if rash, irritation, or worsening symptoms occur. · Keep out of reach of children; store at room temperature away from moisture. |